Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy.

MLA

Sidra, F. N. U., et al. “Glucagon-like Peptide-1 Receptor Agonists versus Dipeptidyl-Peptidase 4 Inhibitors in Advanced Chronic Kidney Disease and End Stage Kidney Disease: Real World Effectiveness and Persistence of Therapy.” Journal of Diabetes and Its Complications, vol. 39, no. 1, Jan. 2025, p. 108925. EBSCOhost, https://doi.org/10.1016/j.jdiacomp.2024.108925.

APA

Sidra, F. N. U., Agarwal, S., Lockhart Pastor, P., Xie, D., Li, X., & Lingvay, I. (2025). Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy. Journal of Diabetes and Its Complications, 39(1), 108925. https://doi.org/10.1016/j.jdiacomp.2024.108925

Chicago

Sidra, F N U, Shubham Agarwal, Paola Lockhart Pastor, Donglu Xie, Xilong Li, and Ildiko Lingvay. 2025. “Glucagon-like Peptide-1 Receptor Agonists versus Dipeptidyl-Peptidase 4 Inhibitors in Advanced Chronic Kidney Disease and End Stage Kidney Disease: Real World Effectiveness and Persistence of Therapy.” Journal of Diabetes and Its Complications 39 (1): 108925. doi:10.1016/j.jdiacomp.2024.108925.